Supplemental Figure 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Autor:	Jennifer A. Pietenpol, Carlos L. Arteaga, Sheau-Chiann Chen, Quanhu Sheng, Yu Shyr, Brian D. Lehmann, Ana M. Grau, Ingrid M. Meszoely, Jenny C. Chang, Andres Forero-Torres, Patrick M. Dillon, Jennifer M. Rosenbluth, Violeta Sanchez, Kimberly C. Johnson, Timothy M. Shaver, J. Scott Beeler, Monica V. Estrada, M. Gabriela Kuba, Melinda E. Sanders, Aditya Bardia, Vandana G. Abramson, Erica L. Mayer, Ingrid A. Mayer, Bojana Jovanović
Rok vydání:	2023
Popis:	Alterations in the PI3K/AKT/mTOR Pathway are not Enriched in Clinical Responders
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b5a0081f6753d879636c99b7da59137 https://doi.org/10.1158/1078-0432.22468118 Zobrazit plný text záznamu